Medi-Fare Drug, Blacksburg, SC

Is Medi-Fare Drug an FDA-registered 503B outsourcing facility?

Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Medi-Fare Drug in Blacksburg, SC, first registered Dec 17, 2013 and most recently registered Dec 31, 2025. FDA lists its last inspection as Jun 6, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Response Letter Issued 12/19/2025”.

FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.

Location on FDA’s list
Blacksburg, SC
Initial registration
Dec 17, 2013
Most recent registration
Dec 31, 2025
Last inspection
Jun 6, 2025
Form 483 issued at last inspection
Yes
Recall after last inspection
No
Action on last inspection
Response Letter Issued 12/19/2025
Intends to compound sterile drugs from bulk substances
Yes

FDA inspections and actions on record

No entry for this facility was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). FDA may list it under a different name, and the page covers actions from 2019 on.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Medi-Fare Drug, Blacksburg, SC (FEI number 3009925820), matched to this page by exact name, city and state. It lists 6 inspections: 2 OAI, 4 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 6, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30099258201273309
May 26, 2023Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30099258201206514
Apr 6, 2017Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30099258201013053
Sep 12, 2014Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3009925820897269
Jun 21, 2013Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3009925820837941
Jan 18, 2013Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3009925820817905

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 25 numbered observations in all, across 3 inspections ending Jul 10, 2015 to Jun 6, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection May 19, 2025 to Jun 6, 2025: 9 observations

Firm on the cover
Medi-Fare Drug Pharmaceutical Compounding, LLC, 300 West Pine Street, Blacksburg, SC 29702
FEI number
3009925820
Establishment type on the cover
Sterile Drug Manufacturer
FDA district office on the cover
FDA / CDER 10903 New Hampshire Ave.. Bldg 51 Rm 4225 Silver Springs, MD 20993 1 301 796 3334
Matched to this page by
FEI number on the cover; linked from 503B list, Data Dashboard, actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically,

A. I visually observed contaminated / stained HEPA filter affecting ISO 5 hood <Redacted B4> in addition to #<Redacted B4> hood <Redacted B4> and hood also have apparent contamination/ stains. To date, no investigation has been pened regarding this apparent contamination.

B. You lack a scientifically established qualification process regarding your media fill unit inspections. You have not demonstrated, via training and qualification, that personnel can accurately and repeatedly detect failing units.

C. You rejected lot <Redacted B4> of repacked Proparacaine HCl 0.5% due to sterile caps coming off of your <Redacted B4> syringes during production. You documented this via INC-24-014 which records the use of <Redacted B4> caps lot These caps had not been scientifically evaluated prior to use to include actions including but not limited to change control, process validation and / or media fills. After this batch rejection, you documented CAP A-24-0O5 which includes the use of a new vendor cap. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.

Specifically,

A. I observed apparent white colored residue and apparent brown or red colored stains on your <Redacted B4> work surfaces in your ISO 5 hood #<Redacted B4>. The apparent white colored residue is also apparent throughout your ISO 5 environment affecting approximately all hoods #<Redacted B4>. The design with th approximate <Redacted B4> of your <Redacted B4> working surfaces offers hard to c ean surfaces. To date, no investigation has been opened regarding this apparent contamination.

B. You have failed to confirm and maintain the cleanliness of your ISO 5 environments.

1. You used <Redacted B4> to generate smoke during your <Redacted B4> airflow pattern evaluations. You have not performed testing to support the adequacy of your cleaning procedures for the presence or absence of <Redacted B4> after you have cleaned and sanitized your ISO 5 environments.

2. ...

Read the full 483 (PDF on fda.gov)

Observation 3

The separate or defined areas and control systems necessary to prevent contamination or mix-ups are deficient.

Specifically,

A. The design of your facility allows for operations to include material flows directly between unclassified areas and your ISO 7 sterile compounding room, "Room <Redacted B4>". Specifically, materials flow from your non-classified "Prep Room" to your ISO 7 compounding room, "Room <Redacted B4> " and from "Room <Redacted B4>" to your non-classified room, "Quarantine Area". Non-classified areas lack continuous monitoring of differential pressures as well as non-viable particles.

B. Air pressure differential limit setpoint alarms and alarm delays are not scientifically established nor monitored regarding your ISO 7 room where you produce sterile drug product(s). You did not establish real-time setpoint limit alarms according to your written SOPs such that your SOP requires differential pressures of <Redacted B4> W.C. Your actual alarm limits are <Redacted B4> W.C. Furthermore, you established alarm delays of approximately <Redacted B4> per your electronic monitoring system and/ or vendor as well as your Quality Director. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

I. The system by which you conduct personnel monitoring is not scientifically established. I observed personnel enter your ISO 5 environment with their hands and arms. You do not currently routinely perform personnel monitoring regarding production personnel forearms.

2. I observed aseptic operators perform finger-tip personnel monitoring after performance of the aseptic connection unit step which includes bulk filling. However, multiple glove changes occurred during this process.

B. Non-Viable Particle (NVP) monitoring is conducted in the ISO 5 hoods. This NVP monitoring is not continuously performed. Furthermore, the firm produces sterile drug products in multiple ISO 5 hoods concurrently and only owns one NVP monitoring device.

Observation 5

Reports of analysis from component suppliers are accepted in lieu of testing each component for confonnity with all appropriate written specifications, without establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.

Specifically, you have not certified that <Redacted B4> water is sterile and nonpyrogenic whereby it is accompanied by a valid COA to ensure the reliability of the supplier's Certificate of Analysis. <Redacted B4> water is used in the production of sterile drug products to include Fentanyl <Redacted B4>, lot <Redacted B4> in <Redacted B4> bags.

REPEAT

Observation 6

Written records of investigations into the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.

Specifically,

A. I observed particulate matter on 5/20/2025 in approximately <Redacted B4> syringes which were a part of your media fill lot <Redacted B4>. These syringes were previously inspected by your furn on 5/07/2025 and 5/15/2025 and were not identified with particulate matter.

B. You documented INC-24-024 on 11/5/2024 for surface plate <Redacted B4> regarding ISO 5 hood # <Redacted B4> was observed with "overgrowth" of Rhizopus-oryzae. Lot <Redacted B4> <Redacted B4> of Phenylepbrine was rejected. Your root cause was inconclusive, and you did not document additional CAPA actions to address this failure.

Observation 7

An adequate number of batches of each drug product are not tested to determine an appropriate expiration date.

Specifically,

You discontinued your stability program in approximately 2018 per your site leadership personnel. You have continued to produce various drug products to include but not limited to Fentanyl <Redacted B4>, lot <Redacted B4> in <Redacted B4> bags, Succinylcholine <Redacted B4>, lot <Redacted B4> in <Redacted B4> syringes. Succinylcholine is produced in lots of <Redacted B4> <Redacted B4> syringes.

Observation 8

Written procedures are not established, written and followed that describe the in-process controls, tests and examinations to be conducted on appropriate samples of in-process materials of each batch.

Specifically,

A. You lack establishment of scientifically justifiable in-process limits regarding visual inspection. Your limit <Redacted B4>% in aggregate for your 100% inspection in addition to your post 100% inspection sample(s). You have not established limits specific to individual defect categories to include but not limited to leakers and particulate matter. You have detected units with fibers and leaking units during your 100% inspection.

B. You lack use ofadequate equipment <Redacted B4> regarding visual inspection. You currently utilize <Redacted B4> backgrounds without adequate lighting.

C. You do not comprehensively document your post 100% inspection sample to support the sample is appropriate numerically and that it represents the entire batch.

Observation 9

Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.

A. Your visual inspection qualification training is inadequate regarding both your initial qualification and your lack of requalification.

THIS PAGE

FORM FDA ~ ()9/08) l'l!EVIOUS tomON 0 6SOLETE INSPECTIONAL OBSERVAllONS PAGE60F 7PAGtS

1. You lack an annual requalification process.

2. Your initial qualification is not scientifically established nor standardized. Your initial visual inspection qualification is conducted via On-the-Job Training only. While you have a defect kit, it is not used to qualify your operators.

3. Your initial qualification process lacks assurance that operators are trained to observe and detect critical, major, and minor defects. ...

Read the full 483 (PDF on fda.gov)

Inspection May 15, 2023 to May 26, 2023: 4 observations

Firm on the cover
Medi-Fare Drug, 300 W Pine St, Blacksburg, SC 29702-1548
FEI number
3009925820
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
60 Eighth Street NE Atlanta, GA 30309
Matched to this page by
FEI number on the cover; linked from Data Dashboard, actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Reports of analysis from component suppliers are accepted in lieu of testing each component for confonnity with all appropriate written specifications, without establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.

Specifically, your firm has not performed any testing of components to ensure the reliability of the supplier's Certificate of Analysis.

Observation 2

The identity of each component of a drng product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.

Specifically, your firm does not conduct any identity testing of raw materials when received. In the last six months, your fnm has compounded approximately <Redacted B4> separate lots that have been or are pending release.

Packaging and Labeling System

Observation 3

Samples of representative lmits were not visually examined for correct labeling at the completion of finishing operations.

Specifically, two batches of Ephedrine Sulfate (25mg/5mL), were manufactured containing an erroneous NDC number on the label. Lot <Redacted B4>, was distributed with the NDC <Redacted B4> instead of the correct NDC <Redacted B4>. Once aware of this complaint your firm conducted an investigation which revealed that a second unreleased batch (Lot <Redacted B4>) contained the same incorrect NDC.

Facilities and Equipment System

Observation 4

Aseptic processing areas are deficient regarding the system for monitoring enviromnental conditions.

Specifically, your firm utilizes <Redacted B4> that are not directly supplied with HEPA-filtered air and rely on a passive supply from a HEPA-filtered, ISO 7 room. This practice may allow introduction of contaminants from an unclassified space.

Inspection dated Jul 10, 2015 by FDA (dates on the form not read): 12 observations

Firm on the cover
, 300 W. Pine Street, CODE
FEI number
3009925820
Establishment type on the cover
Compounding Pharmacy Blacksburg, SC 29702
FDA district office on the cover
12/10-13,18,20/2012; 1 /4,11,16,18/2013 60 Eighth Street, NE Atlanta, GA 30309
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

. There is no assurance that containers, closures, and drug products are free from objectionable

microorganisms.

(a). There is n o documentation available of the REDACTED (B) (4) validations conducted to ensure appropriateness for use prior to REDACTED (B) (4) glassware and finished product.

(b). Section 5.3 of your REDACTED (B) (4), P&P 8.040, dated 9/15/03 require that "monitoring data from each cycle shall be recorded to ensure that processes are performed properly and that all critical parameters are within specified limits during processing". Your firm does not maintain REDACTED (B) (4) cycle printouts to show the cycle parameters were met. During the inspection, sterilization cycle printouts were requested but never received. In addition your REDACTED (B) (4) Use, Cleaning & Spore Testing Log" does not list the lot number of the articles being sterilized, lot number of biological indicators used within the load or document cycle parameters.

(c). There are no records documenting that procedures were followed in the REDACTED (B) (4) verification of your REDACTED (B) (4) cycle, per your procedure entitled, REDACTED (B) (4) Cycle Verification", SOP No. E.023.1, dated 1/11/12. ...

Read the full 483 (PDF on fda.gov)

Observation 2

: Sterility assurance parameters were not met due to your failure to adequately evaluate your REDACTED (B) (4) define appropriate parameters for drug product sterilization, and maintain documentation of sterilization. For example, the following products require REDACTED (B) (4) sterilization per your firm's formulary

worksheets; however no records exist documenting their sterilization:

• Dexamethasone Acetate, Lot 20 120222@3 • Testosterone Aqueous Suspension, Lot 20 120515@3 • Triamcinolone Acetonide Injection 40mg/ml, Lot 20120530@1 • Ciprofloxacin/Dexamethasone Sterile Inj., Lot 20120726@9

Observation 3

: Distribution of the Testosterone Aqueous Suspension 50mg/ml inj., Lot 20120515@3 occurred prior to receipt of final product test results. It was shipped on 5/23/12 and 6/21/12 from your firm, however preliminary results from your contract testing lab were not reported until 10/8/12.

Observation 4

: Vials used in filling sterilized prepara

tions have not b

a validated REDACTED (B) (4) cycle. Managemen t stat ed that such articles are REDACTED (B) (4) using

een rendered free from viable microbes through the use of

the REDACTED (B) (4) cycle of their REDACTED (B) (4). This cycle has not been challenged to ensure it is capable of achieving at least a 3-log reduction in endotoxin levels.

Observation 5

: Records documenting the dates, load cycle, and lot number of vials washed and REDACTED (B) (4) are not been being maintained.

Observation 6

: The current system for monitoring environmental conditions existing within the aseptic processing areas is deficient.

Specifically, (a). Your procedure entitled, "3.060 Environmental Monitoring of the Aseptic Compounding Area: Microbial Organisms", dated 1/4/06, does not describe whether sampling is performed under dynamic conditions; described sampling locations do not correspond to the areas actually sampled; nor does the procedure describe what type of media should be used for incubating such samples.

(b). Personnel monitoring and environmental sampling is not performed and documented during aseptic processing. In addition, gloved fingertip monitoring is only performed as pa rt of REDACTED (B) (4) employee validations. Environmental sampling is performed REDACTED (B) (4).

(c). EnviroTest Monitoring Logs dated 12/27/10-12/5/12 do not include inclusive incubation times, media type and expiration, or document the length of time settling plates were exposed to the environment.

(d). Neutralizing agents are not added to the media, to ensure that the growth potential of such media is not inhibited due to disinfectants applied to surfaces within the clean rooms.

(e). ...

Read the full 483 (PDF on fda.gov)

Observation 7

: There is no documentation that supports the extension of the BUD dates outside of the duration of therapy. Your procedure entitled," Beyond-Use Dating (BUD) of Compounded Preparations", SOP 9.050, sec 9.4 states that," for all other formulations, a BUD is no later than the intended duration of therapy or 30 days, whichever is earlier". For example:

*Testosterone Aqueous Suspension, Lot# 20120515@3, BUD of 5/ 15/13; *Zinc sulfate 1 mg/ml injectable Lot# 20120319@ 12 made on 3/19/12 with BUD of 6/17/12;

* Clonidine/Bupivicaine/Baclofen Pf Intrathecal lot 20110315@4 made on 03/15/11 with BUD of 05/14/11.

Observation 8

: Your firm cites USP <797> and USP <71> as their guidance for sterility and endotoxin testing requirements. As such, sufficient samples in relation to the formulation batch size are not routinely sent to your contract testing lab. For instance:

Glycopyrrolate 0.2mg/ml (5 ml MDV); Lot no. 20121030@8: REDACTED (B)(4) vials; 2-5m! vials sent to lab; Ketorolac Tromethamine 30mg/ml: Lot no. 20120113@4 REDACTED (B)(4) vials; 3-1ml vials sent to lab: Furosemide Inj. 10 mg/ml; Lot no. 201220504@3 REDACTED (B)(4) vials; 3-1 ml vials sent to lab; Metoclopramide Inj 10 mg/ml; Lot no. 20120912@6 - REDACTED (B)(4) units; 4-2ml vials

In addition, there are no quality control procedures addressing the statistical criteria used to justify such sampling size.

Observation 9

: Formulation worksheets are not sufficiently reviewed to ensure accurate and complete information is recorded. The following errors were consistently made without justification: 1. Lot number and expiration dates of chemicals are not recorded or incorrectly recorded; 2. Device lot numbers are not recorded for vials, stoppers, filters used; 3. Formulation instructions were incomplete; 4. Expired chemicals used in formulations, and use of chemicals due to expire prior to the Beyond-Use Date of th e finished product .

Observation 10

: (a).Your firm failed to thoroughly investigate the QREs (Quality Related Events) for Epinephrine

1: 1000 PF Sulfite Free Injectable lots 20121018@9 and 20121024@8 and dispensed from 11/2-11/7/12 with reported pink discoloration, which resulted in the recall of both lots. No units were sent to the contract testing Jab for further testing, nor investigation into previous lots were made to determine root cause and implement corrective actions to prevent reoccurrence.

(b).Sodium Bicarbonate 50 ml vial 8.4% inj., lot 20121115@5 BSC 1/18/13 was found with visible particulate matter, and vials of such lot were bagged and labeled REDACTED (B)(4) . The formulation worksheet however does not denote the presence of particulates, and no additional investigations into the root cause of this quality problem were made. Continuous particulate matter has been noted in additional formulations without any laboratory evaluations.

Observation 11

: There is no documentation of any investigations conducted for over 150 compounded preparations and raw materials that were identified as being "Out of Spec", "Not Pass QA", or Rejected" on destruction logs dated 12/4-7/12.

Observation 12

: There are no written procedures and documentation thereof addressing the subsequent stability, microbial and potency characteristics of stock solutions throughout their labeled Beyond-Use Date, from which multiple aliquots are withdrawn to prepare additional sterile formulations.

Linked 483s whose text is not shown

GLP-1 records in this index

No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Medi-Fare Drug). That is not a finding beyond this index’s search.

The Medi-Fare Drug pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.